TY - JOUR
TI - Advances in biological therapies for dyslipidemias and atherosclerosis
AU - Valanti, E.-K.
AU - Dalakoura-Karagkouni, K.
AU - Siasos, G.
AU - Kardassis, D.
AU - Eliopoulos, A.G.
AU - Sanoudou, D.
JO - Metabolism: Clinical and Experimental
PY - 2021
VL - 116
TODO - null
SP - null
PB - W.B. Saunders
SN - 0026-0495
TODO - 10.1016/j.metabol.2020.154461
TODO - angiopoietin;  angiopoietin like 3;  angiopoietin related protein 4;  antisense oligonucleotide;  apolipoprotein B;  apolipoprotein B100;  apolipoprotein C3;  apolipoprotein mimetic peptide;  biological product;  cholesterol ester transfer protein;  icosapentaenoic acid ethyl ester;  influenza vaccine;  lipoprotein A;  low density lipoprotein receptor;  monoclonal antibody;  oxidized low density lipoprotein;  Pneumococcus vaccine;  proprotein convertase 9;  unclassified drug;  vaccine, atherosclerosis;  biological therapy;  dyslipidemia;  gene editing;  gene targeting;  gene therapy;  human;  immune response;  inflammation;  influenza;  influenza vaccination;  nonhuman;  pneumococcal infection;  priority journal;  Review;  signal transduction;  transcriptomics;  viral gene therapy;  animal;  atherosclerosis;  biological therapy;  dyslipidemia;  endocrinology;  experimental therapy;  procedures, Animals;  Atherosclerosis;  Biological Therapy;  Dyslipidemias;  Endocrinology;  Humans;  Therapies, Investigational
TODO - Atherosclerosis is a multifactorial disease influenced by genetics, lifestyle and environmental factors. Despite therapeutic advances that reduce the risk of cardiovascular events, atherosclerosis-related diseases remain the leading cause of mortality worldwide. Precise targeting of genes involved in lipoprotein metabolism is an emerging approach for atherosclerosis prevention and treatment. This article focuses on the latest developments, clinical potential and current challenges of monoclonal antibodies, vaccines and genome/transcriptome modification strategies, including antisense oligonucleotides, genome/base editing and gene therapy. Multiple lipid lowering biological therapies have already been approved by the FDA with impressive results to date, while many more promising targets are being pursued in clinical trials or pre-clinical animal models. © 2020 Elsevier Inc.
ER -